0001225208-19-000806.txt : 20190110
0001225208-19-000806.hdr.sgml : 20190110
20190110165043
ACCESSION NUMBER: 0001225208-19-000806
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190101
FILED AS OF DATE: 20190110
DATE AS OF CHANGE: 20190110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clyburn Frank
CENTRAL INDEX KEY: 0001763963
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06571
FILM NUMBER: 19520692
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Merck & Co., Inc.
CENTRAL INDEX KEY: 0000310158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 221918501
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
BUSINESS PHONE: 908-740-4000
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
FORMER COMPANY:
FORMER CONFORMED NAME: Merck & Co. Inc.
DATE OF NAME CHANGE: 20091103
FORMER COMPANY:
FORMER CONFORMED NAME: SCHERING PLOUGH CORP
DATE OF NAME CHANGE: 19920703
3
1
doc3.xml
X0206
3
2019-01-01
0
0000310158
Merck & Co., Inc.
MRK
0001763963
Clyburn Frank
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH
NJ
07033
1
EVP, Chief Commercial Officer
Common Stock
61724.9410
D
Common Stock - 401(k) Plan
1395.4461
I
By 401(k)
Phantom Stock
Common Stock
2059.8360
D
Restricted Stock Unit
2019-05-04
2021-05-04
Common Stock
5714.0000
D
Restricted Stock Unit
2020-05-05
2020-05-05
Common Stock
3752.0000
D
Restricted Stock Unit
2019-05-10
2019-05-10
Common Stock
4389.0000
D
Restricted Stock Unit
2019-10-30
2021-10-30
Common Stock
6862.0000
D
Stock Option (right to buy)
39.2900
2013-05-02
2022-05-01
Common Stock
43876.0000
D
Stock Option (right to buy)
44.9800
2014-05-06
2023-05-05
Common Stock
38647.0000
D
Stock Option (right to buy)
54.6800
2017-05-10
2026-05-09
Common Stock
54329.0000
D
Stock Option (right to buy)
57.7500
2019-05-04
2028-05-03
Common Stock
40255.0000
D
Stock Option (right to buy)
58.2200
2015-05-02
2024-05-01
Common Stock
38514.0000
D
Stock Option (right to buy)
58.3300
2016-02-09
2025-02-08
Common Stock
5500.0000
D
Stock Option (right to buy)
59.8600
2016-05-01
2025-04-30
Common Stock
43344.0000
D
Stock Option (right to buy)
63.9700
2018-05-05
2027-05-04
Common Stock
34237.0000
D
Holdings include shares acquired in dividend reinvestment transactions.
Includes shares acquired and dividends earned through January 1, 2019, in the Merck U.S. Savings Plan, a 401(k) plan.
The Merck & Co., Inc. Deferral Program includes the right of redesignation to other investement measures within the Program.
Distributions of phantom stock are made in shares of Common Stock of Merck & Co., Inc., with cash payable for partial shares, in accordance with a distribution schedule elected by the reporting person. This distribution is subject to conditions and limitations of the Merck & Co., Inc. Deferral Program.
1-for-1
These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.
Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.
The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.
The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.
The option became exercisable in equal installments on 5/2/2015, 5/2/2016 and 5/2/2017.
The option became exercisable in equal installments on 2/9/2016, 2/9/2017 and 2/9/2018.
The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.
clyburnpoa.txt
Faye C. Brown as Attorney-in-Fact for Frank Clyburn
2019-01-10
EX-24
2
clyburnpoa.txt
POWER OF ATTORNEY
The undersigned hereby constitutes and appoints each of Faye C. Brown, Katie E.
Fedosz, Jon Filderman, Geralyn S. Ritter and Courtney Ausfahl, signing singly,
the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer of Merck & Co., Inc. (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Forms 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the United States Securities and Exchange Commission and any stock
exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 4th day of January 2019.
/s/ Frank Clyburn